ArticleNature communications2026
The conserved human astrovirus-receptor interface reveals a targetable vulnerability for antiviral development.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Human astrovirus (HAstV) is a major cause of viral enteritis in children and the older adults worldwide. The eight serotypes of classical HAstVs (HAstV1-8), employ the neonatal Fc receptor (FcRn) as an entry receptor. To elucidate the receptor binding mechanism of HAstVs, we determined the crystal structure of the HAstV8 spike protein complexed with human FcRn. The structure reveals that the HAstV8 spike protein engaged FcRn via a conserved surface depression, which is also present across the other seven classical HAstVs serotypes. The binding interface of HAstV8 spike protein on FcRn largely overlaps with the footprints of three clinically approved FcRn blockers to treat an autoimmune disease. Accordingly, these FcRn inhibitors potently suppress astrovirus infection, significantly reducing viral RNA levels in astrovirus permissive Caco2 cells. Therefore, our study reports a conserved receptor recognition mechanism among human astroviruses and suggests the potential of repurposing clinically approved therapeutics to treat astrovirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.